Skip to main content
. 2021 Feb 19;16(2):e0246939. doi: 10.1371/journal.pone.0246939

Table 1. Presence of C5aR1 in the tumour cells of different tumour entities.

Tumour type C5aR1-positive tumours, n Immunoreactive score (IRS)
(total number of cases) mean min max
Glioblastoma (8) 4 3.44 0 9
Meningioma (6) 5 4.17 0 6
Pituitary adenoma (10) 5 2.60 0 6
Thyroid carcinoma (37) 36 5.76 2 10
• papillary (10) 10 5.60 4 8
• follicular (10) 9 4.50 2 8
• medullary (9) 9 5.44 3 8
• anaplastic (8) 8 7.50 6 10
Lung cancer (30) 15 3.15 0 8
• Adenocarcinoma (10) 5 2.95 0 6
• Squamous cell carcinoma (10) 1 1.50 0 4.5
• Small-cell lung cancer (10) 9 5.00 2 8
Breast carcinoma (9) 2 1.22 0 4
Gastric adenocarcinoma (10) 8 4.40 0 6
Hepatocellular carcinoma (10) 10 6.20 4 10
Cholangiocellular carcinoma (9) 8 6.77 2 12
Pancreatic adenocarcinoma (10) 9 4.55 0 12
Pancreatic neuroendocrine tumour (10) 6 2.05 0 4.5
Colon carcinoma (9) 5 3.06 1.5 6
Gastrointestinal stromal tumour (9) 9 8.44 4 12
Pheochromocytoma (6) 0 0 0 0
Renal clear cell carcinoma (7) 7 6.07 4.5 8
Prostate adenocarcinoma (10) 1 1.60 0 6
Testicular cancer (10) 3 1.40 0 4
Ovarian cancer (9) 9 7.89 3 12
Endometrial cancer (10) 10 5.60 4 8
Cervical cancer (9) 8 4.06 2 6
Melanoma (5) 2 2.00 1 4
Lymphoma (10) 8 3.70 2 6
Sarcoma (14) 3 1.36 0 6
• Leiomyosarcoma (4) 0 0.50 0 2
• Rhabdomyosarcoma (3) 2 3.00 0 6
• Pleomorphic sarcoma (2) 0 1.00 0 2
• Liposarcoma (4) 0 0 0 0
• Angiosarcoma (1) 1 6.00 6 6